Revvity, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with the three months ended April 2, 2023. Results reflect continuing operations unless noted. Amounts are in U.S. dollars.
Business context and performance
Revvity operates in Life Sciences and Diagnostics. Revenue was $649.9 million, down 4% from $674.9 million. Management attributed the decline mainly to market headwinds affecting Life Sciences instruments and reagents. Diagnostics was approximately flat.
- Life Sciences: Revenue of $303.0 million, down 8%; segment operating income of $101.7 million, down 21%. Lower sales volume, normalized variable compensation and innovation investment pressured segment margin.
- Diagnostics: Revenue of $347.1 million, up less than 1%; segment operating income of $75.4 million, up 1%. Growth in immunodiagnostics and reproductive health was largely offset by lower applied genomics revenue.
Financial results and liquidity
| Metric | Q1 2024 | Prior-year quarter |
|---|---|---|
| Revenue | $649.9 million | $674.9 million |
| Gross margin | 54.6% | 56.5% |
| Operating income from continuing operations | $44.1 million | $76.1 million |
| Operating margin from continuing operations | 6.8% | 11.3% |
| Income from continuing operations | $28.7 million | $24.8 million |
| Net income | $26.0 million | $569.5 million |
| Diluted EPS from continuing operations | $0.23 | $0.20 |
| Net cash from continuing operating activities | $150.1 million | $71.7 million |
Gross margin declined 188 basis points, primarily from lower volume, partly offset by pricing and productivity. Operating margin also faced higher rebranding and variable-compensation costs. Continuing-operations income increased despite lower operating income, helped by lower interest and other expense, including a smaller foreign-exchange loss than in the prior-year quarter. Prior-year net income included a substantial gain on the sale of discontinued businesses, so the reported net-income comparison is not indicative of continuing performance.
At March 31, 2024, cash and cash equivalents were $998.1 million, marketable securities were $697.3 million, and available revolver capacity was $1.5 billion. Total debt carrying value was approximately $3.88 billion, including $711.5 million of notes due in September 2024. The company intends to use maturing U.S. Treasury securities of $697.3 million toward repayment of those notes. Continuing-operations capital expenditures were $17.8 million; operating cash flow less capital expenditures was approximately $132.3 million, calculated from reported figures. The company paid $8.6 million in dividends and repurchased $10.8 million of stock during the quarter.
Material changes, outlook and risks
- Continuing revenue fell $24.9 million year over year. Life Sciences instruments and reagents decreased, while software increased; Diagnostics strength in immunodiagnostics and reproductive health was offset by applied genomics weakness.
- Continuing operating income fell $32.0 million. Restructuring and other costs were $12.4 million versus $3.1 million, while SG&A increased 5% and R&D decreased 11%.
- Q1 2024 discontinued operations recorded a $2.7 million loss. The prior-year quarter included the sold Applied, Food and Enterprise Services businesses and a significant gain on their sale. Revvity recorded an approximately $161 million receivable for sale-related post-closing adjustments, expected to be received in 2024 but subject to change; it is also due $75 million of brand-related payments in installments through the first half of 2025 and may receive up to $150 million of contingent sale consideration.
- Management expects an approximately 20% effective tax rate on continuing operations for fiscal 2024 before discrete items. No specific revenue or earnings guidance is provided in the filing. Management expects internally generated cash to fund operating costs, capital expenditures, smaller acquisitions, interest and dividends; external funding may be needed for debt maturities, larger acquisitions and other long-term obligations.
- Key disclosed risks include weak or volatile customer markets and order timing, funding and economic uncertainty, foreign-exchange movements, supply-chain disruption, competition and product development, cyber and regulatory risks, and substantial debt. The company reported $14.4 million accrued for environmental matters and stated that other legal contingencies are not expected to have a material adverse effect, while noting outcomes remain uncertain. Goodwill impairment testing as of January 1, 2024 identified no impairment.
Important facts for investors to verify
- Whether Life Sciences demand, especially for instruments and reagents, stabilizes and whether Diagnostics growth can persist.
- Repayment or refinancing of the September 2024 notes and the timing and final amount of the $161 million sale-related receivable.
- Progress on operating margins, restructuring costs, and the expected fiscal 2024 tax rate.
- Potential changes in contingent sale proceeds, environmental accruals, and acquisition-related earnout obligations.
- That prior-year net income and cash flow comparisons include material discontinued-operation and sale-related effects.